TERT and adrenal cortex carcinoma: After combining the results of our study with TERT alterations reported in other studies of adrenocortical carcinomas (Assie et al. 122 cases; Liu et al. 34 cases; Juhlin et al., 41 cases), the overall prevalence of combined amplification (n = 330) and “hotspot” promoter mutation events (n = 364) was approximately 18.2% (Fig. 3) [13, 27, 28].